Dr. Reddy`s Laboratories Ltd. - ADR (RDY) Stock
NEW YORK STOCK EXCHANGE, INC. · RDY
Key stats
- Market cap
- $12.37B
- Price / Earnings ratio
- 27.8x
- EPS (TTM)
- $0.57
- Volume
- Loading
- 52-week high
- $15.67
- 52-week low
- $11.36
- Dividend yield
- 0.87%
- Dividend amount (latest)
- $0.09
Source: third-party data provider, as of November 13, 2026
Compare with RDY
Recent news
Zacks Investment Research
RDY Q2 Earnings & Revenues Miss Estimates as Lenalidomide Sales Fall
NegativeRDYOctober 26, 2026
Zacks Investment ResearchNegative
RDY Q2 Earnings & Revenues Miss Estimates as Lenalidomide Sales Fall
RDY
The Motley Fool
Dr. Reddy's Laboratories: 3 Key Takeaways for Long-Term Investors
NeutralRDYOctober 25, 2026
The Motley FoolNeutral
Dr. Reddy's Laboratories: 3 Key Takeaways for Long-Term Investors
RDY
MarketBeat
Dr. Reddy's Laboratories Q2 Earnings Call Highlights
NeutralRDYOctober 23, 2026
MarketBeatNeutral
Dr. Reddy's Laboratories Q2 Earnings Call Highlights
RDY
Reuters
India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India
PositiveRDYSeptember 18, 2026
ReutersPositive
India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India
RDYNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 72.77
- MACD 12/26/9
- 0.59
- EMA 9 of MACD
- 0.52
- MACD histogram
- 0.07
- SMA 50
- $12.94
- Price above SMA 50
- EMA 50
- $13.35
- Price above EMA 50
- SMA 200
- $13.27
- Price above SMA 200
- EMA 200
- $13.32
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 1 analyst rating
Strong Sell0
Sell0
Hold0
Buy1
Strong Buy0
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Revenue
Net income
Net margin %
2022
2023
2024
2025
2026
68B45B22B0
Debt & Balance Sheet
Total assets
Total liabilities
2022
2023
2024
2025
2026
695B459B229B0
Revenue to Profit
2026$3.7B
Revenue$0.0
Cost of revenue$177.3B
Gross profit$0.0
Operating expenses$42.9B
Net incomeEarnings
EPS forecast
Actual EPS
$0.16
Q3FY26
$0.14
Q4FY26
$0.17
Q1FY27
$0.16
Q2FY27
The market is expecting earnings per share of $0.16 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
Zacks Investment Research
RDY Q2 Earnings & Revenues Miss Estimates as Lenalidomide Sales Fall
NegativeRDYOctober 26, 2026
Zacks Investment ResearchNegative
RDY Q2 Earnings & Revenues Miss Estimates as Lenalidomide Sales Fall
RDYThe Motley Fool
Dr. Reddy's Laboratories: 3 Key Takeaways for Long-Term Investors
NeutralRDYOctober 25, 2026
The Motley FoolNeutral
Dr. Reddy's Laboratories: 3 Key Takeaways for Long-Term Investors
RDYMarketBeat
Dr. Reddy's Laboratories Q2 Earnings Call Highlights
NeutralRDYOctober 23, 2026
MarketBeatNeutral
Dr. Reddy's Laboratories Q2 Earnings Call Highlights
RDYReuters
India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India
PositiveRDYSeptember 18, 2026
ReutersPositive
India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India
RDY
Business Wire
Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
RDYAugust 20, 2026
Business Wire
Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
RDY
Business Wire
Dr. Reddy's Laboratories (RDY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
RDYAugust 20, 2026
Business Wire
Dr. Reddy's Laboratories (RDY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
RDY
Business Wire
Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
RDYAugust 19, 2026
Business Wire
Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
RDY
Business Wire
RDY SHAREHOLDER ALERT: Dr. Reddy's Laboratories Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
RDYAugust 14, 2026
Business Wire
RDY SHAREHOLDER ALERT: Dr. Reddy's Laboratories Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
RDY
Business Wire
Dr. Reddy's Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States
RDYAugust 4, 2026
Business Wire
Dr. Reddy's Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States
RDY
Business Wire
RDY Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Dr. Reddy's Laboratories (RDY)
RDYJuly 28, 2026
Business Wire
RDY Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Dr. Reddy's Laboratories (RDY)
RDYNews tone: automated (AI) classification of the article's content, not a price prediction.
About Dr. Reddy`s Laboratories Ltd. - ADR
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees27,527
CEOMr. Erez Israeli M.B.A.
IPO DateApr 11, 2001
HeadquartersHyderabad, India
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Erez Israeli M.B.A. | CEO & Member of the Management Council | 1968 |
| Mr. Deepak Sapra M.B.A. | CEO ? API and Services & Member of Management Council | 1975 |
| Mr. Motupalli Venkata Ramana M.B.A. | CEO of Global Generics & Member of Management Council | 1969 |
| Mr. Gunupati Venkateswara Prasad B.E. | Co-Chairman, MD & Member of Management Council | 1960 |
| Mr. Kallam Satish Reddy B.Tech., M.S. | Chairman of the Board & Member of the Management Council | 1967 |
| Mr. Mannam Venkatanarasimham | CFO & Member of the Management Council | 1970 |
| Mr. Sanjay Sharma B.Tech. | Executive VP, COO & Member of Management Council | 1968 |
| Mr. Krishna K. Venkatesh B.Pharma M.S. | Global Head of IPDO, Integrated Product Development & Member of the Management Council | 1973 |
| Mr. Patrick Aghanian B.A., M.B.A. | Head of Consumer Health Organization & Member of Management Council | 1965 |
| Mr. Bhethanabottla S. Phanimitra | Chief Digital & Information Officer and Member of the Management Council | 1980 |
Fundamentals
Valuation
Price-to-sales ratio3.32
Price-to-book value2.95
PEG ratio1.98
Profitability
EBITDA$885.79M
Trading
Average volume2,979,452
Dividend
Ex dividend date24 Jul 2026
Last payment date5 Aug 2026
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 72.77
- MACD 12/26/9
- 0.59
- EMA 9 of MACD
- 0.52
- MACD histogram
- 0.07
- SMA 50
- $12.94
- Price above SMA 50
- EMA 50
- $13.35
- Price above EMA 50
- SMA 200
- $13.27
- Price above SMA 200
- EMA 200
- $13.32
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Analyst consensus:Buy
100% Buy
0% Hold
0% Sell
Analyst price target
- Low
- $1,450.00
- Average
- $1,450.00
- High
- $1,450.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -4.5 | +6.3 | ||||||||||
| 2022 | -11.9 | -6.6 | +5.9 | -3.8 | +3.7 | +0.3 | -7.8 | +1.6 | -1.3 | +0.3 | +1.0 | -7.8 |
| 2023 | +4.0 | -3.1 | +7.0 | +5.4 | -9.4 | +13.1 | +9.8 | -1.9 | -1.8 | -2.0 | +6.7 | +0.0 |
| 2024 | +1.6 | +6.1 | -1.9 | -0.7 | -7.2 | +9.7 | +7.8 | +1.1 | -2.0 | -7.2 | -4.8 | +10.4 |
| 2025 | -11.8 | -6.1 | +3.4 | +5.8 | +6.4 | +2.0 | -4.8 | +1.9 | -1.0 | -6.4 | +4.8 | +0.7 |
| 2026 | -3.2 | +5.7 | -3.7 | +1.3 | -0.7 | +9.3 | -15.3 | +0.5 | +3.7 | +15.7 | +5.0 |
Corporate actions
Upcoming
No upcoming corporate actions for RDY
Past
DividendQ3/26
Ex-dividend date24 Jul 2026
Payable date5 Aug 2026
Amount per share$0.08
DividendQ3/25
Ex-dividend date25 Jul 2025
Payable date6 Aug 2025
Amount per share$0.09
DividendQ3/24
Ex-dividend date30 Jul 2024
Payable date12 Aug 2024
Amount per share$0.48
DividendQ3/23
Ex-dividend date28 Jul 2023
Payable date11 Aug 2023
Amount per share$0.48
DividendQ3/22
Ex-dividend date1 Aug 2022
Payable date12 Aug 2022
Amount per share$0.38
Compare stocks
Market cap
$12.37B
-
-
-
Price / Earnings ratio
27.80
-
-
-
Price / Sales ratio
3.32
-
-
-
Dividend yield
0.87%
-
-
-
Average volume
2,979,452
-
-
-
Earnings per share
$0.57
-
-
-
